{
  "guideline": {
    "id": "PA166104966",
    "name": "Annotation of DPWG Guideline for tamoxifen and CYP2D6",
    "source": "DPWG",
    "version": 30,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104966",
    "relatedChemicals": [
      {
        "id": "PA451581",
        "name": "tamoxifen",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302762",
      "name": "Recommendation Annotation PA166302762",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104361,
        "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302766",
      "name": "Recommendation Annotation PA166302766",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104365,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302842",
      "name": "Recommendation Annotation PA166302842",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104441,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302744",
      "name": "Recommendation Annotation PA166302744",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104343,
        "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302726",
      "name": "Recommendation Annotation PA166302726",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104325,
        "html": "<p>Select an alternative or increase the dose to 40 mg/day and monitor the endoxifen concentration. Studies have demonstrated that PM can achieve an adequate endoxifen concentration when the dose is increased to 40-60 mg/day. Aromatase inhibitors are a possible alternative for post-menopausal women.</p>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302761",
      "name": "Recommendation Annotation PA166302761",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104360,
        "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302821",
      "name": "Recommendation Annotation PA166302821",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104420,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302765",
      "name": "Recommendation Annotation PA166302765",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104364,
        "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302843",
      "name": "Recommendation Annotation PA166302843",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104442,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302743",
      "name": "Recommendation Annotation PA166302743",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104342,
        "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302764",
      "name": "Recommendation Annotation PA166302764",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104363,
        "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302742",
      "name": "Recommendation Annotation PA166302742",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104341,
        "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302781",
      "name": "Recommendation Annotation PA166302781",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104380,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302801",
      "name": "Recommendation Annotation PA166302801",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104400,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302763",
      "name": "Recommendation Annotation PA166302763",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104362,
        "html": "<p>The guideline does not provide a recommendation for tamoxifen in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on tamoxifen."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302741",
      "name": "Recommendation Annotation PA166302741",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104340,
        "html": "<ul>\n<li>Select an alternative or measure the endoxifen concentration and increase the dose if necessary, by a factor of 1.5-2. Aromatase inhibitors are a possible alternative for post-menopausal women.</li>\n<li>If TAMOXIFEN is selected: avoid co-medication with CYP2D6 inhibitors such as paroxetine and fluoxetine.</li>\n</ul>\n"
      },
      "implications": [
        "This gene variation reduces the conversion of tamoxifen to the active metabolite endoxifen. This can result in reduced effectiveness."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302767",
      "name": "Recommendation Annotation PA166302767",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104366,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302841",
      "name": "Recommendation Annotation PA166302841",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA451581",
          "name": "tamoxifen",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452104440,
        "html": "<p>NO action is needed for this gene-drug interaction.</p>\n"
      },
      "implications": [
        "As a result of the genetic variation, the plasma concentration of the active metabolites 4-hydroxytamoxifen and endoxifen can increase. However, there is no evidence that this results in an increase in the side effects."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011
    }
  ],
  "version": "2023-12-19-10-38"
}